Clinical Trial Update: A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg [Phase 4]

View source ↗

Summary

Phase 4 trial comparing three proton-pump inhibitor regimens (rabeprazole 20 mg, esomeprazole 20 mg, and esomeprazole 40 mg) in gastroesophageal reflux disease;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Esomeprazole 20 mg (esomeprazole)
• Esomeprazole 40 mg (esomeprazole)
• Rabeprazole sodium 20 mg (rabeprazole)

Snippet

Sponsor: Janssen-Cilag Pty Ltd | Conditions: Gastro-oesophageal Reflux | Phase 4 | Status: COMPLETED | Results posted: 2010-08-30